Symptomatic tumor progression was suspected in 2018, leading to a surgical tumor biopsy that demonstrated WHO grade 4 <i>IDH1</i> and <i>IDH2</i> mutant diffuse astrocytoma. The gene discussed is IDH1; the disease is diffuse astrocytoma.